股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2026年1月31日 狀態: 新提交 | 2. 股份分類 | 優先股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | 否 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | N/A | 說明 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 100 | HKD | | HKD | | 77,300,000 | | 增加 / 減少 (-) | | | | | | HKD | | | | 本月底結存 | | | 100 | HKD | | HKD | | 77,300,000 | 本月底法定/註冊股本總額： HKD 277,300,000 公司名稱: 建滔集團有限公司 呈交日期: 2026年2月3日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1 ...

香港联交所最新数据显示，1月26日，FMR LLC减持建滔集团（00148）463.35万股，每股作价31.2782 港元，总金额约为1.45亿港元。减持后最新持股数目约为8739.61万股，最新持股比例为7.89%。 香港联交所最新数据显示，1月26日，FMR LLC减持建滔集团（00148）463.35万股，每股作价31.2782 港元，总金额约为1.45亿港元。减持后最新持股数目约为8739.61万股，最新持股比例为7.89%。 责任编辑：卢昱君 热点栏目 自选股 数据中心 行情中心 资金流向 模拟交易 客户端 热点栏目 自选股 数据中心 行情中心 资金流向 模拟交易 客户端 责任编辑：卢昱君 ...

Group 1 - FMR LLC reduced its stake in Kintor Pharmaceutical (00148.HK) by selling 4.6335 million shares at an average price of HKD 31.2782 per share, amounting to approximately HKD 145 million [1] - Following the sale, FMR LLC's total shareholding decreased to 87.39614 million shares, representing a reduction in ownership from 8.30% to 7.89% [1]

香港联交所最新数据显示，1月26日，FMR LLC减持建滔集团(00148)463.35万股，每股作价31.2782港 元，总金额约为1.45亿港元。减持后最新持股数目约为8739.61万股，最新持股比例为7.89%。 ...

智通财经APP获悉，香港联交所最新数据显示，1月26日，FMR LLC减持建滔集团(00148)463.35万股， 每股作价31.2782港元，总金额约为1.45亿港元。减持后最新持股数目约为8739.61万股，最新持股比例 为7.89%。 ...

Group 1 - The core viewpoint of the article highlights the positive performance of Jiantao Group and its subsidiaries, driven by the growth in the PCB and CCL industries due to AI infrastructure expansion [1] - Jiantao Laminated Board (01888) saw an increase of 5.47%, reaching HKD 15.23, while Jiantao Group (00148) rose by 1.67%, reaching HKD 31.62 [1] - Goldman Sachs reported that the Chinese PCB and CCL industries are experiencing a dual trend of "acceleration and scaling," benefiting leading companies through specification upgrades, increased shipment volumes, and capacity expansion [1] Group 2 - Guotai Junan Securities noted that Jiantao has raised prices three times since August 2025, with an unexpected increase in December, indicating a positive pricing cycle across the entire industry chain driven by AI demand [1] - The company is strategically positioned in copper foil, electronic cloth, and copper-clad laminates, suggesting that as an industry leader, it is likely to benefit from the price increase cycle across all segments [1]

Group 1 - The Hong Kong stock market saw a rise in the shares of Kwan Tong Group, with Kwan Tong Laminated Board (01888.HK) increasing by 5.47% to HKD 15.23 [1] - Kwan Tong Group (00148.HK) also experienced a gain, rising by 1.67% to HKD 31.62 [1]

Core Viewpoint - The report highlights that the Chinese PCB (Printed Circuit Board) and CCL (Copper Clad Laminate) industries are experiencing a dual trend of "acceleration and scaling" driven by the AI infrastructure boom, benefiting leading companies through specification upgrades, increased shipment volumes, and capacity expansion [1] Group 1: Company Performance - Jiantao's stock prices have risen, with Jiantao Laminated Board (01888) up by 5.47% to HKD 15.23 and Jiantao Group (00148) up by 1.67% to HKD 31.62 [1] - Jiantao has implemented price increases three times in August, October, and December, with an additional unexpected price hike in December, indicating a positive pricing cycle across the entire industry chain driven by AI demand [1] Group 2: Industry Trends - According to Goldman Sachs, the PCB and CCL industries are benefiting from a robust growth cycle due to AI infrastructure, leading to significant growth opportunities for top-tier companies [1] - The industry is entering a favorable price increase cycle, with Jiantao positioned as an integrated leader benefiting from price hikes across copper foil, electronic cloth, and copper clad laminates [1]

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年12月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 建滔集團有限公司 呈交日期: 2026年1月2日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 00148 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 2,000,000,000 | HKD | | 0.1 | HKD | | 200,000,000 | | 增加 / 減少 (-) | | | | | | | HKD | | | | 本月底結存 | | | 2,000,000,000 | HKD | | 0.1 | HKD | | 200,000,000 | | 2. 股份分類 | ...

Group 1 - China Merchants Securities maintains an "Accumulate" rating for JD Health (06618.HK), highlighting its "medicine + pharmacy" dual-driven model and leading market share in retail pharmacies, with O2O delivery times as fast as 9 minutes [1] - China Everbright Securities International maintains an "Accumulate" rating for Biren Technology (06082.HK), noting its position as the first company in China to use 2.5D chip packaging technology and its strong commercial progress with over 2 billion yuan in unfulfilled orders [1] - Huachuang Securities maintains a "Strong Buy" rating for Hesai Technology (02525.HK), emphasizing its leadership in the global LiDAR market and significant cost reductions achieved through self-developed chips, with a delivery target of 200,000 units by 2025 [1] Group 2 - CICC maintains an "Outperform" rating for Haidilao (06862.HK), reporting stable table turnover rates in H2 and better-than-expected cost optimization, with new brand strategies accelerating growth [2] - CICC maintains an "Outperform" rating for Shuangdeng Co. (06960.HK), identifying it as a leader in communication and data center energy storage, benefiting from increased capital expenditure in global AIDC and the trend of lithium battery replacing lead-acid [2] Group 3 - CITIC Securities maintains a "Buy" rating for Kintor Group (00148.HK), noting the positive impact of price increases on its CCL business and the expected growth in PCB business volume [3] - CITIC Securities maintains a "Buy" rating for Shougang Resources (00639.HK), highlighting its resource scarcity and leading cost control, with expected performance growth amid rising coking coal prices in 2026-27 [3] - Shenwan Hongyuan maintains a "Buy" rating for Beautiful Garden Medical Health (02373.HK), emphasizing its accelerated industry consolidation through acquisitions and a significant increase in store numbers [3] - China Merchants Securities maintains an "Accumulate" rating for Baiguoyuan Group (02411.HK), noting its stock incentive plan and strategic upgrades aimed at restoring same-store growth and opening pace [3]